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ABSTRACT
RYAN C. PERKINS: Characterization of the Lipopolysaccharide Binding Site on the
Plasma Protein High Molecular Weight Kininogen

Bradykinin(BK)participates in the control of local blood flow and blood pressure by
causing vascular hyperemia and vascular inflammation. The Bradykinin generating
pathway of human plasma consists of prolylcarboxypeptidase(PRCP), prekallikrein
(PK), and high molecular weight kininogen(HK). When the complex of HK-PK
assembles on endothelial cells or an artificial negatively charged surface,PK is
immediately converted to kallikrein by the enzyme PRCP. The formed kallikrein then
autodigests HK to liberate BK. The BK that is formed then plays an important role in
vascular permeability by stimulating constitutive Bradykinin B2 and inducible B1
receptors to release prostacyclin and nitric oxide. Thus, the activity ofPRCP leads to
vasodilation. In inflamed tissues, tissue injury or hypotensive bacteremia, BK has been
shown to accumulate in the blood or plasma of patients. Since LPS possesses a
negatively charged surface and the ability to stimulate an inflammatory response, the
interaction of LPS with the proteins ofthe Bradykinin generating pathway assessed and
characterized. These studies showed that the binding of LPS to HK was time dependent,
dose dependent, saturable and reversible. The binding of LPS to HK was shown to occur
via the positively charged amino acid residues of domain 5 interacting with the
negatively charged moieties of LPS. The binding ofLPS to HK was further shown to be
maximal at pH 7.0 and in an isotonic environment. The binding of LPS to HK was
blocked by HKH19, endotoxin free C1-Inhibitor, heparin, and W-acetylglucosamine
glycan but not by lipid A with IC50S of 15 nM,20 fig/ml, 10 nM and 10 mM,

IV

respectively. This novel study highlights the role HK plays in infection. This study
proposes that HKH19,heparin and Cl-Inhibitor present therapeutic potential for the
I

treatment of hypotensive bacteremia and sepsis.
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I. INTRODUCTION

A. Plasma Kallikrein System
The Plasma Kallikrein Kinin System(KKS)plays an important role in the
activation and increase ofthe inflammatory response to tissue injury and in patients with
septic shock, hypotensive bacteremia, in rhesus monkeys infected with Salmonella
typhimurium and upon exposure to negatively charged surfaces.^’^’*® Composed ofthree
serine protease zymogens Prekallikrein(PK), Factor XII(FXII) and Factor XI(FXI)and
a nonenzymatic procofactor High Molecular Weight Kininogen(HK),the KKS is
induced at the onset of an inflammatory response by the binding ofa HK-PK complex
and FXII to the surface ofan endothelial cell or other biological activating surface. Upon
adhering to the cell membrane, FXII is converted to an alternate form (FXIIa) and PK is
converted to Kallikrein by the serine protease Prolylcarboxypeptidase(PRCP)and FXIIa.
The formed Kallikrein will then autodigest HK to release Bradykinin(BK)and an
3,5

alternate form ofHK (HKa).

HK is a multifunctional, multidomain /?-globulin protein

with a molecular weight of 120 kDa and has a physiological concentration of80 /ig/ml
(670nM).^ The activated FXIIa then aids in the conversion ofFactor XI to Factor XIa.
This activation induces the intrinsic coagulation pathway also known as the contact
system.^
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Figure 1: Autodigestion of High Molecular Weight Kininogen.
HK consists of6 domains arranged into a single chain. HK is further divided into a
heavy chain which consists of Domains 1 through Domain 3 and a light chain that
contains Domain 5H and Domain 6. Domain 4 contains the amino acid sequence for BK
which links the heavy chain and the light chain together. When PK is converted to
Kallikrein by PRCP,the formed Kallikrein will cleave HK to break the disulfide bond
between the heavy chain and the light chain to release BK.^

2

B. Prolylcarboxypeptidase
Prolylcarboxypeptidase(PRCP)is a serine protease commonly found in
endothelial cells and plays an important role in modulating numerous vasoactive
hormones and protein precursors that are involved in blood pressure regulation.
Originally, PRCP was characterized as an exopeptidase that cleaves small, biologically
active peptides at the carboxy terminus, typically the Pro-Phe bond, at neutral pH and at
pH’s of less than 7.0. When the serine protease was extracted and purified fi*om human
umbilical vein endothelial cells(HUVEC),it was found to be a PK activator. Prior
experiments have shown that PRCP isolated from endothelial cell lysates, Chinese
Hamster Ovary cell lysates and recombinant PRCP purified fi'om Schneider 2 insect cells
will only activate PK when coupled to its receptor on HK. In vi\o control ofPRCP
utilizes the endogenous inhibitors: Cl inhibitor,(X2-macroglobulin and antithrombin
In addition, to catalyzing the conversion ofPK to Kallikrein,PRCP has also been shown
to catalyze the hydrolysis of angiotensin II(Ang II) to angiotensin 1-7(Ang 1-7) and
angiotensin III(Ang III) to angiotensin 2-7(Ang 2-l)J This degradation of Ang II to
Ang 1-7 has lead to PRCP’s characterization as an Ang II degrading enzyme. Upon
investigations ofPRCP’s catalytic ability on Ang II, PRCP was found to have a

of
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200 /xM.

Recent studies examining the colocalization ofPRCP revealed that the protein

is present on the cell surface and in lysosomes. The studies also revealed that PRCP
colocalizes with gClqR, urokinase plasminogen activator receptor(uPAR),and
cytokeratin 1; however, does not completely colocalize with lysosomal associated
protein.^

3

C. Bradykinin
Bradykinin plays an important role in the causation of vascular inflammation and
in the regulation of local blood flow and blood pressure. BK is a vasodilator and a potent
stimulator of tissue plasminogen activator release.^ Under normal conditions in the
cardiovascular and renal systems, blood pressure regulation occurs via the Bradykinin B2
receptor(BKJB2R). BKB2Rs are found in abundance in the tissues ofthe cardiac, renal
and vascular systems. Literature reports that BKB2Rs exert their effects by activating
vasoactive components of the prostaglandin-Nitric Oxide cascade.*
Prior studies have shown that Bradykinin effects are mediated by the
constitutively active BKB2R and by inducible Bradykinin B1 receptors(BKBIR). It has
been shown that BKBlRs are activated in cardiac, renal, and vascular tissues by stimuli
including tissue damage, bacterial lipopolysaccharides, and cytokines. The BKBlRs are
1,4

most commonly induced during the inflammatory response and nociceptive reactions.
Like the BKB2Rs,the BKBlRs are known to play an important role in normal blood
pressure regulation. In pharmacological experiments utilizing genetically engineered
BKB2R knockout mice, the mildly h>pertensive rats have shown that increasing salt or
exogenous angiotensin II concentrations induced greater levels of hypertension and also
displayed higher levels of BKBIR gene activity."*
As mentioned earlier, the KKS plays an important role in responding to
inflammation. The KKS can utilize two distinct pathways to respond to chronic
inflammation and acute inflammation. In order to initiate an acute inflammatory
response, the KKS system is activated. Leukocytes then marginate within the blood
vessel and migrate towards the site of the inflammatory response. The stimulation of

4

BKB1R then causes cell adhesion molecules to become activated and play an important
role in the regulation of the neutrophils’ adhesion cascade. HKa then complexes to
neutrophils and monocytes that are present at the site ofthe inflammatory response and
inhibit their binding to fibrinogen. This prevents them from migrating and ensures their
presence at the site of injury. Due to the chemotactic properties of Kallikrein, neutrophil
aggregation is induced. This in turn stimulates the release of elastase and superoxide
which serve as potent inducers oftissue injury. In addition, intracellular signaling and
the release and synthesis of other mediators generating pain (prostaglandin release),
vascular dilation (prostaglandin I2), or permeability(endothelial nitric oxide synthase)
occur due to activation of BKB2Rs and cell adhesion molecules.^
As a result of a chronic inflammatory response, HKa binds directly to monocytes
and neutrophils on urokinase-type plasminogen activator receptors(uPAR)and Mac-I
located on the surface of monocytes and neutrophils. This in turn upregulates the
production and release of cytokines tumor necrosis factor(TNF)-d,interleukin (IL)-l/3,
chemokines monocyte chemoattractant protein(MCP)l and IL-8 from monocytes and
superoxide and elastase from neutrophils. These released factors play an essential role in
inducing tissue injury and eventually chronic inflammation. Eventually, HKa is
inactivated by proteases in the course ofits biological nine hour half-life.^
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Figure 2: Role of the Kallikrein-Kinin System in inflammation.
The KKS can utilize two distinct pathways to respond to chronic inflammation and acute
inflammation.
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D. Nitric Oxide
Nitric Oxide(NO)is a two-atom compound that is synthesized physiologically by
various tissue and cell types in the body and plays a complex role in physiology. In the
cardiovascular system, NO acts as a mediator of vasodilation in the endothelium helping
to regulate vessel tone, but also plays a role in the regulation ofplatelet aggregation,
leukocyte adhesion, paracrine and autocrine pathways involving control of vascular cell
growth and remodeling, endothelial cell apoptosis, migration and organization. NO
synthesis from L-arginine in endothelial cells is catalyzed by the enzyme Nitric Oxide
Synthase(eNOS). Studies have shown that physiologically eNOS is activated by
increasing the levels ofintracellular calcium present. The increasing calcium levels will
in turn upregulate the binding ofcalmodulin to eNOS. eNOS,a transmembrane protein,
is found on Golgi and caveolar membranes; however,the targeting ofeNOS to caveolae
is dependent upon co- and post-translational modification (myristoylation,
palmitoylation) which are required for optimal enzymatic activity.^

E. Renin-Angiotensin System
The Renin-Angiotensin System (RAS),similar to Bradykinin, plays an important
role in the regulation of blood pressure and the vascular response to injury. This
relationship can be illustrated due to the dual roles ofRAS in the homeostasis ofsalt and
water in the body’s response to vascular injury. Damage to the endothelial wall can be
caused due to the increased mechanical strain that is associated with high blood pressure.
When RAS is activated, the blood pressure is increased which leads to the causation of a
local inflammatory response to aid in repairing the injury. Due to elevated blood

7

pressure and angiotensin Il-induced oxidative stress, continual response to this injury
leads to microvascular damage and endothelial dysfunction. This response has
pathophysiological effects increasing the chances of myocardial infarction, heart failure.
11

stroke, peripheral arterial disease, and renal disease.

The Renin Angiotensin System plays an important role in protecting the heart,
endothelium, brain and kidney from sustained exposure to blood pressures that exceeds
the physiological range through a complex system ofneuroendocrine interactions.
Continual activation of RAS results in the causation of hypertension and activates a
cascade of proinflammatory, prothrombotic and atherogenic effects. The synthesis ofthe
central metabolite Ang I is largely dependent upon the activity of renin. Renin, an
enzymatic hormone that plays an important role in salt regulation by the kidneys, is
synthesized and released by the liver to counter act decreases in renal perfusion pressure.
This released renin then catalyzes the conversion of angiotensinogen into the inactive
peptide Angiotensin I(Ang I, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu). As the
central metabolite of RAS, Ang I can then follow three different paths. Ang I can be
converted into the vasoactive peptide Ang II(Asp-Arg-Val-Tyr-He-His-Pro-Phe) by
angiotensin-converting enzyme(ACE). In this conversion, ACE cleaves the His-Leu
residues from the carboxy terminus ofthe peptide. Surprisingly, not all ofthe conversion
from Ang I to Ang II is done by ACE. In fact, nearly ~ 40% ofthe conversion is
catalyzed through chymase, cathepsin G,and other serine proteases. The formed Ang II
is then known to interact with at least 2 different receptors, angiotensin II receptor
subtype 1 (ATi)and angiotensin II receptor subtype 2(AT2). Ofthe two Ang II receptor
subtypes, the AT1 receptor has been more readily characterized and is understood in
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greater depth. Widely distributed throughout the body, the ATi receptors with ligand
bound leads to vasoconstriction, release of aldosterone by the adrenal glands, promotes
the retention of salt and water and activates vascular remodeling. Since activation ofthe
AT1 receptors causes increases in oxidative stress and transforming growth factor ft it
contributes to the proinflammatory, atherogenic, and prothrombotic environment. The
binding of Ang II to ATi receptors can be blocked by the ATi antagonist, angiotensin
12

receptor blocker.

Although not as readily understood, the AT2 receptor is normally activated as a
result of tissue injury and exerts its effects on cardiovascular tissue that are
counterregulatory to those regulated by ATi receptors.*^ The exact effects ofthe AT2
receptor have not been completely characterized; however, experiments involving AT2deflcient mice revealed that these receptors are involved in regulating the cellularity of
atherosclerotic lesions. In studies where the AT2 receptor was overexpressed, an
attenuation of perivascular and cardiac fibrosis was observed upon exposure to Ang II.
In addition, the activation ofthe AT2 receptor may also be beneficial due to the activation
oftheICKS.
In addition to Ang I being converted to Ang II, Ang I can also be converted to
Ang 1-7 by neutral endopeptidase. The formed Ang 1-7 then binds to the AT1.7 receptor
which plays an important role in activating angiotensin-converting enzyme 2(ACE2).
The activation of ACE2 is counterbalanced by the ATi receptor which plays an important
role in inhibiting the activity of ACE2. ACE2 plays an important role in the regulation of
Ang II to Ang 1-7. If ACE2 is activated by the AT1.7R, then it can catalyze the
conversion of Ang II to Ang 1-7. However,if the ATi receptor is activated, ACE2 is

9

inhibited, thus preventing the conversion of Ang II to Ang 1-7. The third fate of Ang I is
12

its conversion to Ang 1-9 by ACE2.

F. Kallikrein-Kinin System Counterbalances Renin-Angiotensin System
As mentioned earlier, the KKS plays an important role in RAS by acting as an
essential counterbalance, due to the ability ofPRCP to interact in the KKS or RAS,the
role of ACE,the interactions of Bradykinin and Ang 1-7 and the differing effects of
activating ATi and AT2 receptors. As stated earlier, PRCP is a known PK activator
converting PK to Kallikrein, which causes HK to be cleaved releasing BK and HKa.
However,PRCP is also an important player in activating RAS. When PRCP converts PK
into Kallikrein, it also catalyzes the conversion of Prorenin to Renin initiating the RAS
cascade. In addition, PRCP plays an important role further down the cascade due to its
ability to convert Ang II to Ang 1-7. Although PRCP plays a role in this conversion.
ACE2 is 100-fold kinetically better at degrading Ang II to Ang 1-7 with a Km of
inactivation of2 mM.This relationship is significant due to the end physiological result
of each system. By activating KKS, vasodilation occurs due to the production of NO and
prostacylin, where as activating RAS can lead to vasodilation or vasoconstriction. If
RAS is activated and PRCP is inhibited, Ang II will lead to vasoconstriction through the
AT 1 Receptor. However, if RAS and PRCP are activated, Ang II will be converted to
Ang 1-7, which will lead to vasodilation and formation of NO and prostacyclin. This
13

relationship allows for the KKS to counterbalance RAS.

In addition, the KKS serves as a counterbalance to RAS due to the interaction
between Ang 1-7 and BK. The best studied interactions between Ang 1-7 and the KKS

10

G. Lipopolysaccharide
Lipopolysaccharide(LPS)is an endotoxin that encompasses areas ofthe cell wall
in Gram-negative bacteria. When LPS is administered to an organism,it has the potential
to induce an inflammatory response, which ifsevere enough can lead to multiple organ
disfunctions, septic shock and death. In addition to its location in the cell wall of Gramnegative bacteria, LPS is an immune stimulant which induces the release of(TNF)-d, BL1 and IL-6. These pro-inflammatory cytokines play an essential role in mediating the
physiological effects of LPS and are involved in the modulation ofthe central nervous
14

system-mediated responses.

H. Experimental Rationale
Although the KKS can perform differently in response to different conditions,PK
can only be activated when complexed to HK on the cell membrane surface or when
bound to a negatively charged moiety. Since LPS contains a negative surface and is
capable of eliciting an inflammatory response, studies were conducted to characterize the
interaction between LPS and HK. The findings of this study may play an integral role in
the development of new drug therapies to treat infection.

12

II. MATERIALS AND METHODS

Materials.
Prekallikrein(PK)with a specific activity of27 U/mg was purchased from
Enzyme Research Laboratories(South Bend, IN). S2302, a chromogenic substrate, was
purchased from Chromogenics, Inc.(Lexington, Mass). Single chain High Molecular
Weight Kininogen(HK)with a molecular weight of 120 kDa on reduced SDS-PAGE and
a specific activity of 13 U/mg in acetate buffer(4 mM sodium acetate-HCl and 0.15 M
NaCl, pH 5.3) was purchased from DiaPharma Laboratories, Inc.(West Chester, OH).

Binding ofbiotin-HK to LPS.
The biotinylated binding studies were conducted by adding LPS at 2 fig/ well in a
microtiter plate and incubating overnight at 4° C with 0.1 M Na2C03,pH 9.6. The next
day, the wells were blocked with 1% gelatin for 1 hour at 37° C. After 1 hour,the cells
were washed with Hepes-NaHCOs buffer[137 mM NaCl,3 mM KCl, 12 mM NaHCOs,
14.7 mM Hepes, 5.5 mM Dextrose, and 0.1% gelatin, pH 7.1] containing 2 mM CaCb,
and 1 mM MgCL,blocked with 1% gelatin at pH 7.1 in the presence and absence of50fold molar excess HK and then incubated with 20 nM biotin-HK for 1 hour at 37° C. The
binding of biotin-HK to LPS was ascertained using ImmunoPure streptavidin horseradish
peroxidase conjugate and peroxidase-specific fast reacting substrate, 3,3’,5,5’-

13

tetramethylbenzidine dihydrochloride(TMB)as suggested by Pierce(Rockford, H). The
binding of biotin-HK to LPS was determined quantitatively by measuring the absorbance
ofthe reaction mixture in a microplate auto reader ELX 800 Bio-Tek Instrument
(Winooski, VT)at 450 nm. The total binding of biotin-HK to LPS was determined and
compared with the level of binding observed in the presence of a 50-fold molar excess of
HK.

Binding ofbiotin-LPS to HK.
A 96 well microtiter plate was coated with 2 fig ofHK in 0.1 M NazCOs,pH 9.6
overnight at 4° C. The next day, the wells were washed three times with Hepes-NaHCOs
buffer containing 2 mM CaCL and 1 mM MgCL and then blocked with 1% gelatin for 1
hour at 37° C. After blocking, the HK bound to the microtiter plate was washed and then
incubated in the absence and presence ofincreasing concentrations of biotin-LPS in
Hepes-NaHCOs buffer for 1 hour at 37°C. The binding of biotin-LPS to HK was
ascertained using ImmunoPure streptavidin horseradish peroxidase conjugate and
peroxidase-specific fast reacting substrate, 3,3’,5,5’-tetramethylbenzidine
dihydrochloride(TMB). The binding of biotin-LPS to HK was determined quantitatively
by measuring the absorbance ofthe reaction mixture in a microplate auto reader at 450
nm. The total binding of biotin-LPS to HK was determined and compared with the level
of binding observed in a 100-fold molar excess of LPS.

14

Inhibtion ofbiotin-LPS binding to HK.
2 lig of HK in 0.1 M Na2C03, pH 9.6 was coupled to a 96 well microtiter plate
and incubated overnight at 4°C. The next day the wells were blocked with 1% gelatin for
1 hour at 37° C. After blocking, the microtiter plate wells were washed and incubated
with 3-5 /xg/ml of biotin-LPS in Hepes-carbonated buffer in the absence or presence of
various concentrations of HKH19[19 amino acid residues of HK’s domain 5, diethyl
pyrocarbonated HKH19(modified HKH19),endotoxin free heparin, Cl-inhibitor,
cytokeratin 1 (CKl), urokinase plasminogen activator receptor(uPAR), glucose,fucose,
sucrose, A^-acetylglucosamine gylcan, and lipid A for 1 hour at 37° C. After incubation,
the binding of biotin-LPS to HK was ascertained using ImmunoPure streptavidin
horseradish peroxidase conjugate and peroxidase-specific fast reacting substrate,
3,3’,5,5’-tetramethylbenzidine dihydrochloride(TMB). The binding of biotin-LPS to HK
was determined quantitatively by measuring the absorbance ofthe reaction mixture in a
microplate auto reader at 450 nm.

Endothelial cell culture.
Human umbilical vein endothelial cells(HUVEC)were purchased from Clonetics
(San Diego, CA)and cultured according to the vendor’s instructions. Confluent cells
(>3.0 X lO'^/cm^)at passage numbers one to five were used in the assays.
Lipopolysaccharide {Escherichia coli serotype 0111:B4) was diluted in endothelial cell
growth medium and exposed to cells between 1 and 24 hours with a final concentration
of 1-1000 ng/ml.

15

n

I
I

Statistical analyses.
Results are expressed as means ± SEM,and data was analyzed using Student’s ttest for significant difference. Statistical significance was defined as P ^.05.
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III. RESULTS

A. Characterization of LPS interaction with HK

i. Time-course of biotin-LPS binding to HK: Since PK can be activated only
by PRCP when properly assembled to HK on the cell membrane surface or on a
negatively charged moiety, the effect of LPS on the assembly ofthe HK-PK complex and
the activation of the complex on endothelium was characterized. Studies were initially
conducted to characterize the interactions that occur between biotinylated-LPS(BLPS)
and HK. In these studies, 2 ^g/well ofHK or BSA was coupled to a 96 well microtiter
plate overnight and was followed by the addition ofBLPS. The addition of5 /ig/ml of
BLPS to the microtiter plate containing HK resulted in increased binding between BLPS
and HK over time (Figure 3). However, incubation ofBLPS with the microtiter plate
covered with BSA did not result in increased binding over time. These data suggest that
LPS binds to HK and that the binding occurs in a time-dependent manner.

17
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Figure 3: Time Course of biotin-LPS binding to HK.
Investigations were performed to determine if biotin-LPS could bind HK. HK or BSA
was coupled to microtiter plates followed by treatment with biotin-LPS over a period of
time. The amount of bound BLPS was then measured by the absorbance of the reaction
mixture at 450 nm.
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ii. Influence of pH and osmolarity on the binding of biotinylated-LPS to HK:
According to literature, suggestions have been made that the pH at the site of
inflammation could be slightly acidic with a pH ofabout 6.5. In order to characterize the
optimum pH for binding of LPS to HK,studies were conducted at various pH ranges and
at different salt concentrations. When the pH of the buffer was adjusted, there was a
marked change in the binding constant of LPS to HK (Figure 4). According to the pH
studies, the binding of LPS(5 fig/m\) to HK(2 /tg/ml) coated to the microtiter plate was
maximal at pH 6.8-7.0.
When salt concentrations were increased from a hypotonic environment(200
mOsm)to an isotonic environment(335 mOsm)the binding ofLPS(5 /ig/ml)to HK(2
/xg/ml) exhibited an increase in the binding affinity(Figure 5). The highest binding of
LPS to HK occurred at 335 mOsm. When the salt concentrations were altered, LPS
binding to HK was inhibited at high salt concentrations. The data from this study also
showed that the binding of LPS to HK in a 96 well microtiter plate was optimal at
physiological salt concentrations. These data suggest that optimal binding ofLPS to HK
occurs in a slightly acidic and isotonic environment.
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Figure 4: The influence of pH on biotin-LPS binding to HK.
In these studies the binding of biotin-LPS (5 fig/rnl) to HK(2 /ig/ml) that was linked to a
96 well microtiter plate was investigated under different pH conditions. The amount of
bound BLPS was then measured by the absorbance ofthe reaction mixture at 450 nm.
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Figure 5: The effect of osmolarity on biotin-LPS binding to HK.
In these studies the effect of biotin-LPS (5 jug/ml) binding to HK (2 fig/ml) linked to a 96
well microtiter plate was investigated as var3dng osmolarities. The amount of bound
BLPS was then measured by the absorbance of the reaction mixture at 450 nm.

21

iii. Determination of the binding of biotinylated LPS(BLPS)to HK: Since
prior studies revealed that LPS binding to HK occurred in a time-dependent manner at an
optimum pH and osmolarity, studies were performed to determine whether the binding of
LPS to HK occurred in a dose-dependent manner. In doing this, HK or BSA was coupled
to a 96 well microtiter plate and then treated with 0.0 to 10.0 ^g/ml concentrations of
BLPS. The data from this study showed that the binding ofBLPS to HK was saturable
and that half maximal binding occurred at 0.7 jLtg/ml (Figure 6). When a 96 well
microtiter plate containing HK was treated with 0.0 to 10.0(ig/ml ofBLPS and a fifty
molar excess of HK,BLPS binding to HK linked to the plate was blocked. This
interaction suggests that the binding was specific.
In order to determine if HK binding to LPS was dose-dependent 2 jug/ml ofLPS
was linked to a 96 well microtiter plate and incubated with 0.0 to 10 nM biotin-HK
(Figure 7). Similar to the results ofthe previous study, the binding ofbiotin-HK to LPS
bound to the microtiter plate was found to be saturable and that half maximal binding
occurred at 6 nM (0.7 fig/ml). Likewise, when BSA was treated with increasing
concentrations of biotin-HK little binding occurred between the BSA and HK. These
combined data suggested that LPS would bind to HK. However, this finding may not
reflect their actual physiological interaction due to the fact that LPS bound to HK at
concentrations where LPS is 100-fold higher than it is found in the blood of patients with
sepsis or in the plasma.
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Figure 6: Binding Studies with Biotin-LPS.
In these studies 10 ng/ml to 10 jitg/ml of biotin-LPS(BLPS)or BLPS with a 50 M excess
of HK were incubated with 2 fxg/well ofHK or BSA linked to a 96 well microtiter plate
at 37°C. The amount of bound BLPS was then measured by the absorbance ofthe
reaction mixture at 450 nm.
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Figure 7: Binding Studies with Biotin-HK.
In these studies 0.01 to 10 nM of biotin-HK(BHK)were incubated with 2 /rg/well of
LPS or BSA linked to a 96 well microtiter plate at 37°C. The amount ofBHK that was
bound to LPS was then calculated by measuring the absorbance at 450 nm ofthe reaction
mixture.
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B. Inhibition Studies
i. Mapping LPS binding site(s) on HK: Previous studies have demonstrated
that HK can bind to various unrelated proteins found on endothelial cells via the cell
binding domain, HKH19. In order to determine if LPS binding to HK occurred through
HKH19, HK (2 fig/m\) was linked to a 96 well microtiter plate and treated with LPS(3
/ig/ml) and increasing concentrations ofHKH19(Figure 8). HKH19 was found to inhibit
the binding of LPS to HK in a dose-dependent manner.
Due to the belief that hydrophobic amino acid residues are vital for LPS
interaction with the target protein, studies were performed to assess whether the positive
amino acid residues on HKH19 could non specifically attract the negatively charged
moiety of LPS. In this study, histidine residues on the HKH19 were covalently modified
to A^-ethyloxyformyl-histidine by using diethyl pyrocarbonate. HKH19 was incubated
with 1 mM diethyl pyrocarbonate at room temperature for 5 hours. The free diethyl
pyrocarbonate was extracted by overnight dialysis in gelatin free Hepes-NaHCOs buffer.
When increasing concentrations of modified HKH19 was added with LPS(3 ^g/ml)to
HK(2 /Ag/ml) linked to a 96 well microtiter plate, the modified HKH19 blocked the
binding of LPS to the linked HK in a dose-dependent manner. HKH19 and modified
HKH19 inhibited the binding of biotin-LPS to HK with IC50S of20 nM and 50 nM,
respectively. The data from these studies suggested that LPS primarily binds to lysine
amino acid residues that are present within the HKH19.
Since the negatively charged moiety of LPS was shown to non-specifically attract
HKH 19, the effect of heparin and Cl-Inhibitor, positively charged species, were
determined on LPS binding to HK. When heparin was added in increasing
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concentrations it was shown to inhibit the binding ofLPS to HK with an IC50 of0.3 U
heparin/ml (Figure 9). Furthermore, when heparin was administered in the presence of
physiological concentration of HK(600 nM), it was shown to inhibit LPS’s ability to
bind to HK linked to the microtiter plate. In agreement with the literature, this finding
suggested the high affinity of heparin for the domain 5 ofHK. Since heparin possesses a
high content of anionic sulfates and carboxylates, these data confirmed our hypothesis
that the interaction of lysine residues of HKH19 to heparin or to LPS is an ionic
interaction.
When Cl-Inhibitor, which possesses a net cationic charge, was added in a dosedependent manner it was shown to block LPS binding to HK linked to a 96 well
microtiter plate and possessed an IC50 of20 /tg/ml (Figure 10). This result suggests that
the binding between LPS and Cl-Inhibitor is a direct interaction.
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Figure 8: The effect of HKH19 on the binding of LPS to HK.
In this study HKH19 or diethyl pyrocarbonated HKH19 was reported to block LPS
binding to HK, 0.001 to 1 fiM of HKH19 or diethyl pyrocarbonated in the presence of
biotin-LPS (BLPS) was incubated with 2 /ig/well of HK that was linked to a 96 well
microtiter plate. The amount of BLPS that was bound to HK was then calculated by
measuring the absorbance of the reaction mixture at 450 nm.
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Figure 9: The effect of Heparin on LPS binding to HK.
In this study Heparin or Heparin with 600 nM HK was reported to block LPS binding to
HK. 0.0001 to 100 unit/ml of endotoxin free heparin or heparin plus 600 nM HK in the
presence of BLPS was incubated with 2 ^g/well ofHK that was linked to a 96 well
microtiter plate. The amount of BLPS that was bound to HK was then calculated by
measuring the absorbance of the reaction mixture at 450 nm.
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Figure 10: The effect of Cl-Inhibitor on LPS binding to HK.
In this study Cl-Inhibitor was reported to block BLPS binding to HK. Various
concentrations of Cl-Inhibitor in the presence ofBLPS was incubated with 2 ^g/well of
HK that was linked to a 96 well microtiter plate. The amount of BLPS that was bound to
HK was then calculated by measuring the absorbance ofthe reaction mixture at 450 nm.
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ii. Mapping HK binding site(s) on LPS: Next studies were conducted to
determine the HK binding site(s) on LPS. Since LPS is composed ofa carbohydrate
moieties, the effects of monosaccharide, disaccharide, and polysaccharide were
investigated to determine its effect of LPS binding to HK. Studies investigating the
effects of glucose, fucose, sucrose, deoxyglucose, and galactose showed little effect on
the binding of LPS(3 /xg/^ml) to HK(2 ^rg/ml) that was linked to the microtiter plate.
When A^-acetylglucosamine glycan was investigated, it blocked the binding ofbiotin-LPS
to HK in a dose-dependent manner(Figure 11). Furthermore, A^-acetylglucosamine
glycan inhibition possessed an IC50 of 10 mM.
Next studies these studies were repeated to determine ifthese carbohydrates and
lipids would effect HK binding to LPS linked to a microtiter plate. Likewise, glucose,
fucose, sucrose, deoxyglucose and galactose again had little effect ofHK(2 /ig/ml)
binding to LPS(3 /rg/ml) that was linked to microtiter plate(Figure 12). Again, when Aacetylglucosamine glycan was investigated, it blocked the binding ofbiotin-HK to LPS
linked to microtiter plate in a dose-dependent manner and possessed an IC50 200 mM.
Due to the fact that LPS also contains Lipid A moieties, studies were conducted to
determine the effect of different concentrations of Lipid A on the binding ofbiotin-LPS
to HK linked to microtiter plate. Data from this study reveal that the binding of biotinLPS to HK was unchanged by the presence of Lipid A(Figure 13). The data from these
studies implied that the main site in which HK binds to LPS is the polysaccharide sidechains of LPS.
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Figure 11: The effect of sugars on LPS binding to HK.
In this study increasing concentrations of flicose, glucose, sucrose and acetyl glucosamin
glycan in the presence of BLPS was incubated with 2 /ig/well ofHK that was linked to a
96 well microtiter plate. The amount of BLPS that was bound to HK was then calculated
by measuring the absorbance of the reaction mixture at 450 nm.
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Figure 12: The effect of sugars on HK binding to LPS.
In this study increasing concentrations offucose, glucose, sucrose and acetyl glucosamin
glycan in the presence of BHK was incubated with 2 ^g/well ofLPS that was linked to a
96 well microtiter plate. The amount ofBHK that was bound to LPS was then calculated
by measuring the absorbance of the reaction mixture at 450 nm.
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Figure 13: The effect of Lipid A on LPS binding to HK
In this study increasing concentrations of Lipid A in the presence of20 nM BLPS was
incubated with 2 /xg/well of HK that was linked to a 96 well microtiter plate. The amount
of BLPS that was bound to HK was then calculated by measuring the absorbance ofthe
reaction mixture at 450 nm.
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IV. DISCUSSION
Since PK can only be converted to Kallikrein when HK is bound to the cell
membrane surface or an artificial negative surface and LPS possesses a negatively
charged domain with the ability to induce an inflammatory response in humans,the
interaction of LPS and HK was determined. In this study we show that the binding of
LPS to HK occurs in a time dependent, dose dependent, saturable and reversible manner.
The interaction of LPS on HK was shown to occur via the positively charged
Lysine residues on domain 5. Furthermore, this interaction can be inhibited by HKH19,
diethyl pyrocarbonated HKH19, and heparin. In addition, this study shows that the HK
binding site on LPS is the polysaccharide chain. Inhibition ofthis interaction occurred by
A^-acetylglucosamine glycan and C1-Inhibitor. These data reveal that LPS binds to HK
and this interaction possesses insights that might potentially be utilized in treating
patients with hypotensive bactermia and sepsis.
In order to further characterize this interaction, a set of competitive inhibition
studies were undertaken based on the prior data that was collected. Our data suggests
that the attraction of C1 -Inhibitor for LPS outcompetes the binding of LPS to HK. It is
reasonable to speculate that this interaction of Cl-Inhibitor with LPS might lead to the
continual amassing of Kallikrein and activated FXII during endotoximea. In addition, the
ability of heparin to inhibit LPS binding to HK was not affected in the presence or
absence of physiological concentration of HK(600 nM). This data could be applicable to
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future studies to determine if HK is involved in the removal offree heparin from
systemic circulation in patients suffering from sepsis.
The activation of the Kallikrein Kinin System plays an important role in hypertension and
inflammation. Therefore, the KKS metabolites play an integral role in health and disease.
Since the KKS system is responsible for the production ofBK and HKa,our data
emphasizes the importance of HK,BK, and HKa in infection. However,further
investigations need to be undertaken in order to characterize its predictive values in
inflammation.
Furthermore, our data further provides evidence that HK plays a protective role in
the coagulation system against infection. Our interesting and novel method of
characterizing the inhibition of microbial binding (via HKH19,heparin, and Cl-inhibitor)
to the cell surface, should be further investigated with clinical studies, as it possesses
potential therapeutic implications for patients with sepsis and hypotensive bactermia.
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